Respiratory arrest

Bell Law Firm and Steele Adams Hosman File Medical Malpractice Lawsuit Following the Death of 19-Year-Old Utah Woman

Retrieved on: 
Wednesday, April 12, 2023
Legal, Professional Services, Intermountain Medical Center, State, Life, Intermountain Health, Respiratory arrest, Life flight, Florida Third District Court of Appeal, MCFD, Ventilation, Wood, EMS, District court, Utah Highway Patrol, Drug, CT scan, Death, Hypoxia (medical), Nursing, IMC

As a result, Gwen rapidly went into respiratory arrest.

Key Points: 
  • As a result, Gwen rapidly went into respiratory arrest.
  • According to Alyssa Wood, an attorney at Steele Adams Hosman, the medication error is a “never event,” the type of medical error that should never occur.
  • “As a result of the overdose,” states Wood, “a young woman lost her life, and two families lost their daughter and eldest sibling.”
    “This is a tragic and egregious case of negligence,” says Lloyd Bell, an attorney at Bell Law Firm.
  • “After bypassing safety protocols, multiple EMS providers administered Gwen a massive overdose of high-risk medication.

Innocoll and DURECT Announce U.S. launch of POSIMIR®

Retrieved on: 
Monday, September 26, 2022
Central nervous system, Injection, Safety, Bradycardia, Achievement, Patient, U.S. Securities and Exchange Commission, Bupivacaine, Technology, C-reactive protein, Pain management, Annual report, Headache, AH, Risk, Fatty liver disease, COVID-19, Respiratory arrest, Methemoglobinemia, Sale, Food, Diarrhea, Vomiting, Anesthetic, Bruise, Surgeon, DNA, Nausea, SEC, Patent, Dizziness, Allergy, Coma, FDA, NASH, Association, Shoulder joint, Tinnitus, Paresthesia, Form 10-K, Chondrolysis, United States patent law, Somnolence, SABER, Constipation, Marketing, Itch, Blood, Incidence, Hypersensitivity, Elective surgery, Private Securities Litigation Reform Act, Regulation of tobacco by the U.S. Food and Drug Administration, Chronic liver disease, CNS, Anemia, Dentistry, Pharmaceutical industry, Vaccine, Fever, Dysuria, Dysgeusia, Hypoesthesia

"We are excited to bring a potential cornerstone of multi-modal post-operative pain management to surgeons with the launch of POSIMIR," said Louis Pascarella, Chief Executive Officer of Innocoll.

Key Points: 
  • "We are excited to bring a potential cornerstone of multi-modal post-operative pain management to surgeons with the launch of POSIMIR," said Louis Pascarella, Chief Executive Officer of Innocoll.
  • Per the terms of the collaboration between Innocoll and DURECT, Innocoll will make a $2 million payment to DURECT triggered by the first commercial sale of POSIMIR.
  • Previously, in August 2022, DURECT was issued a new patent by the US Patent Office, extending US patent coverage of POSIMIR to at least 2041, resulting in an $8 million milestone payment by Innocoll to DURECT.
  • NOTE: POSIMIR is a trademark of Innocoll Pharmaceuticals Limited in the U.S. and a trademark of DURECT Corporation outside of the U.S. SABER is a trademark of DURECT Corporation.

Masimo Debuts Telehealth for Patient SafetyNet™ at HIMSS 2022 Global Health Conference

Retrieved on: 
Monday, March 14, 2022
Telecommunications, Software, Audio, Video, Health, Medical Devices, Data Management, Hospitals, Technology, DOI, University, Securities Act of 1933, Continuity, Anesthesia, U.S. Securities and Exchange Commission, Communication, HIMSS, Private Securities Litigation Reform Act, Oxygen saturation (medicine), Premature, Vizient, Inc., PVI, Carboxyhemoglobin, BMJ, Drug Quality and Security Act, Rx, Patient safety, McGrath, FDA, Multimedia, Respiratory arrest, Securities Exchange Act of 1934, Quality, Patient, SEC, CEO, MASI, NASDAQ, Ventricular septal defect, Automation, U.S. News & World Report, Nursing, Telehealth, Mortality, Conference, Radius, Risk, Methemoglobin, Sale, Security (finance), 2021 Essex County Council election, Solution, Analgesic, Anesthesiology, ICU, Gateway, Retinopathy, Disease, Efficiency, Hospital, Iloilo, News, Technology, Motion, Ori, Software, TODA, RD, Medical device, Medical imaging, Masimo, Design, COVID-19

Today at the 2022 HIMSS Global Health Conference, Masimo (NASDAQ: MASI) announced a major expansion of Masimo Patient SafetyNet, its premier hospital remote patient monitoring and clinician notification platform, with the addition of secure telehealth capabilities making an already powerful solution even more versatile and comprehensive.

Key Points: 
  • Today at the 2022 HIMSS Global Health Conference, Masimo (NASDAQ: MASI) announced a major expansion of Masimo Patient SafetyNet, its premier hospital remote patient monitoring and clinician notification platform, with the addition of secure telehealth capabilities making an already powerful solution even more versatile and comprehensive.
  • Telehealth for Patient SafetyNet offers a host of additional advanced features designed to further improve workflow efficiency and accommodate as many communication and patient scenarios as possible.
  • Just as telehealth for Masimo SafetyNet makes it possible for clinicians and patients to meet from afar, telehealth for Patient SafetyNet allows clinicians to collaborate and communicate in sophisticated but intuitive and efficient ways, ultimately helping to improve patient outcomes and reduce the cost of care.
  • Masimo hospital automation and connectivity solutions are centered around the Masimo Hospital Automation platform, and include Iris Gateway, iSirona, Patient SafetyNet, Replica, Halo ION, UniView, UniView :60, and Masimo SafetyNet.

Masimo Announces FDA Clearance of Pediatric Indication for SedLine® Brain Function Monitoring and the SedLine Pediatric EEG Sensor

Retrieved on: 
Monday, February 28, 2022
Technology, Medical Devices, Surgery, Children, Hospitals, FDA, Software, Hardware, Consumer, Health, News, Ori, Anesthesia, Disease, Securities Exchange Act of 1934, Security (finance), Hospital Universitario La Paz, Anesthesiology, Retinopathy, RD, PVI, Private Securities Litigation Reform Act, Hospital das Clínicas, U.S. News & World Report, Solution, Premature, ICU, MASI, Risk, SEC, Oxygen saturation (medicine), Sale, Continuity, Securities and Exchange Commission (Philippines), Rx, DSA, Multimedia, BMJ, Securities Act of 1933, Drug Quality and Security Act, CEO, Respiratory arrest, McGrath, DOI, Iloilo, NASDAQ, Carboxyhemoglobin, Methemoglobin, United, Brain, Patient, Technology, Automation, Patient safety, Motion, Radius, University, Ventricular septal defect, Quality, Mortality, FDA, Gateway, EEG, 2021 Essex County Council election, Analgesic, Vizient, Inc., Seizure, Hospital, Medical imaging, Medical device, COVID-19, Design

Masimo (NASDAQ: MASI) announced today the FDA clearance of SedLine brain function monitoring for pediatric patients (1-17 years of age) and the SedLine Pediatric EEG Sensor.

Key Points: 
  • Masimo (NASDAQ: MASI) announced today the FDA clearance of SedLine brain function monitoring for pediatric patients (1-17 years of age) and the SedLine Pediatric EEG Sensor.
  • Equipped with Masimos advanced signal processing technology, SedLine helps clinicians monitor brain activity bilaterally by processing electroencephalogram (EEG) signals from Masimos four-lead SedLine EEG sensors.
  • Joe Kiani, Founder and CEO of Masimo, said, SedLine is achieving for brain function monitoring what Masimo SET did for pulse oximetry.
  • These forward-looking statements include, among others, statements regarding the potential effectiveness of Masimo SedLine and the SedLine Pediatric EEG Sensor, as well as their FDA clearane for pediatric patients.

Innocoll Announces Successful Completion of Debt Refinancing

Retrieved on: 
Friday, January 28, 2022
Pharmaceutical, Health, Surgery, Risk, Bradycardia, Paresthesia, Headache, Diffusion, Coma, Anesthetic, Research, Bupivacaine, Shoulder joint, US Foods, City, Injection, Diarrhea, Safety, Seroma, Somnolence, Association, Anemia, Elective surgery, Tremor, Company, Oaktree Capital Management, Investment, Hospital, CNS, Toxicity, Methemoglobinemia, Tinnitus, Oak Tree, Respiratory arrest, Itch, Â, Blurred vision, Hypersensitivity, List of life sciences, GPC, Incidence, Constipation, Industry, FDA, Liver, Northwest Biotherapeutics, Chondrolysis, Blood, Vomiting, Patient, Food, Central nervous system, Allergy, Bruise, Nausea, Dizziness, Hydrogen chloride, Surgeon, C-reactive protein, Dentistry, Medical device, Dietary supplement, Vaccine, Pharmaceutical industry, Dysuria, Fever, Dysgeusia, Hypoesthesia

Aman Kumar, Co-Portfolio Manager of Life Sciences Lending at Oaktree, said, We are pleased to partner with Innocoll at this exciting stage in the companys development.

Key Points: 
  • Aman Kumar, Co-Portfolio Manager of Life Sciences Lending at Oaktree, said, We are pleased to partner with Innocoll at this exciting stage in the companys development.
  • Innocoll Biotherapeutics plc is a global specialty pharmaceutical company headquartered in Athlone, Ireland.
  • Innocoll Biotherapeutics plc and its subsidiaries Innocoll Holdings Limited and Innocoll Pharmaceuticals Limited, are focused on the development and commercialization of pharmaceutical technologies to meet some of todays most important healthcare challenges.
  • Innocoll Biotherapeutics plc is a portfolio business of Gurnet Point Capital.

DURECT and Innocoll Announce a $136 Million U.S. Licensing Agreement for POSIMIR® (Bupivacaine Solution)

Retrieved on: 
Wednesday, December 22, 2021
Blood, Technology, CNS, Dizziness, Association, COVID-19, Anesthetic, Risk, Respiratory arrest, Headache, Bruise, Food, Clinical trial, DNA, U.S. Securities and Exchange Commission, Shoulder joint, Patient, Vomiting, Somnolence, Webcast, Fatty liver disease, Elective surgery, Nausea, SEC, Diarrhea, AH, SABER, Chronic liver disease, Tinnitus, Coma, Anemia, Fast track (FDA), Injection, Safety, Central nervous system, Bradycardia, Security (finance), Hypersensitivity, Calendar, Paresthesia, Bupivacaine, Boxed warning, Itch, Allergy, C-reactive protein, Methemoglobinemia, Review, NASH, Chondrolysis, Incidence, Constipation, FDA, Vaccine, Pharmaceutical industry, Fever, Dysgeusia, Dysuria, Hypoesthesia

Innocoll Biotherapeutics plc and its subsidiaries Innocoll Holdings Limited and Innocoll Pharmaceuticals Limited, are focused on the development and commercialization of pharmaceutical technologies to meet some of today's most important healthcare challenges.

Key Points: 
  • Innocoll Biotherapeutics plc and its subsidiaries Innocoll Holdings Limited and Innocoll Pharmaceuticals Limited, are focused on the development and commercialization of pharmaceutical technologies to meet some of today's most important healthcare challenges.
  • At the end of surgery, POSIMIR is administered into the subacromial space under direct arthroscopic visualization, where it continuously releases bupivacaine for 72 hours or more.
  • Inadvertent intravascular injection could cause POSIMIR droplets to be deposited in the pulmonary and other capillary beds.
  • Direct arthroscopic visualization must be used to confirm proper placement of the needle tip before injecting POSIMIR.

Anesthesia Disposables Global Market Report 2021 Featuring Ambu A/S, Medline Industries, Smiths Medical, Teleflex and Vyaire Medical - ResearchAndMarkets.com

Retrieved on: 
Friday, August 6, 2021
Pharmaceutical, Health, Medical Supplies, KSR International Co. v. Teleflex Inc., Arthritis, Respiratory disease, Nurse anesthetist, Prevalence, Press Uncuffed, Population, COVID-19, Pediatrics, Patient, Tidal volume, Airway management, Oxygen, Heat and moisture exchanger, Anesthesiology, Cardiovascular disease, Pain, Respiratory arrest, Ageing, HME, ETT, Child, Thyroid disease, Dentistry

The "Anesthesia Disposables Global Market Report 2021: COVID-19 Implications and Growth to 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Anesthesia Disposables Global Market Report 2021: COVID-19 Implications and Growth to 2030" report has been added to ResearchAndMarkets.com's offering.
  • Major players in the anesthesia disposables market are Ambu A/S (Denmark), Medline Industries, Inc. (USA), Smiths Medical, (USA), Teleflex, Inc. (USA) and Vyaire Medical Inc. (USA).
  • The anesthesia disposables market consists of sales of anesthesia disposables and related services.
  • These disposables include onetime use anesthesia circuits, anesthesia masks, sample lines, filters/Heat & Moisture Exchangers (HMEs), breathing bag, endotracheal tubes, and laryngeal masks.

New Study Investigates the Impact of ORi-Guided Oxygen Titration on Hyperoxemia-Mediated Morbidity During One-Lung Ventilation

Retrieved on: 
Monday, June 14, 2021
Practice Management, Nursing, Surgery, General Health, Health, Medical devices, Hospitals, Clinical trials, Medicine, Clinical medicine, Health care, Cardiology, Medical monitoring, Pulse oximetry, Respiratory therapy, Oxygen therapy, Respiratory arrest, Masimo

Moreover, in our study, it was revealed that these patients had a longer hospital stay.

Key Points: 
  • Moreover, in our study, it was revealed that these patients had a longer hospital stay.
  • Oxygen Reserve Index Guided Oxygen Titration in One Lung Ventilation with Low Fresh Gas Glow.
  • Impact of pulse oximetry screening on the detection of duct dependent congenital heart disease: a Swedish prospective screening study in 39,821 newborns.
  • Inpatient Respiratory Arrest Associated With Sedative and Analgesic Medications: Impact of Continuous Monitoring on Patient Mortality and Severe Morbidity.

Deaths in Toronto Shelters at All Time High: CEO of Heart to Heart CPR Says That Shelter Staff is Taking the Wrong Course – A Claim Recently Supported by Newest Canadian 2020 Resuscitation Guidelines Released October 19, 2020

Retrieved on: 
Wednesday, October 21, 2020
Medical emergencies, Respiratory arrest

Currently Toronto shelters do not require these lifesaving devices (See Toronto Shelter Standards 11.2 Safety Standards) .

Key Points: 
  • Currently Toronto shelters do not require these lifesaving devices (See Toronto Shelter Standards 11.2 Safety Standards) .
  • If ventilations are not provided quickly or effectively during Respiratory Arrest, the brain begins to get damaged within 4-6 minutes.
  • By the time EMS arrives, if there is no bystander care, the person has a lower survival rate.
  • The highest number of deaths in shelters occurred in 2019 when there were 48 (an average of four deaths per month).

Novel Airway Management System by Hospitech, Reduces Ventilation Complications in Lung Transplantation

Retrieved on: 
Wednesday, November 6, 2019
Medicine, Medical specialties, Clinical medicine, Airway management, Intensive care medicine, Respiratory therapy, Emergency medicine, Mechanical ventilation, Advanced airway management, Lung transplantation, Respiratory arrest, Sedation

It describes the successful use of the AnapnoGuard system in postoperative management of lung transplant patients.

Key Points: 
  • It describes the successful use of the AnapnoGuard system in postoperative management of lung transplant patients.
  • The data demonstrates quantitative removal of secretions and effective airway cuff pressure management.
  • Major risks and complications can occur following lung transplantation, with prolonged mechanical ventilation, increasing the risk of bacterial colonization and infections.
  • Hospitech Respiration Ltd. is an Israeli medical device company, focused on developing and marketing of advanced airway management solutions for mechanically ventilated patients.